|
Patent landscape, scope, and claims: |
Patent Landscape Analysis: US 8,207,297
What is the Core Technology Protected by US Patent 8,207,297?
United States Patent 8,207,297, titled "STEROID AND HORMONE THERAPY," was granted on June 26, 2012, to R.P. Scherer Technologies, Inc. The patent claims methods of treating hormone deficiencies and improving sexual function in both men and women through the administration of specific androgen and estrogen compounds. The primary focus is on novel formulations and delivery methods designed to achieve consistent and predictable therapeutic levels of these hormones. The patent specifically addresses formulations involving a combination of testosterone and estradiol, or their esters, intended for intramuscular injection. The claimed innovation lies in the particular esterification of these hormones and the composition of the injectable vehicle to ensure sustained release over a defined period, typically weeks.
What Specific Claims Does US 8,207,297 Cover?
The patent's claims delineate the protected subject matter. Claim 1, a representative independent claim, defines a method for treating a human subject experiencing a deficiency in androgen and/or estrogen. This method involves administering an intramuscular injection comprising a composition containing testosterone cypionate and estradiol cypionate. The specified dosage ranges and the sustained release profile of the injected composition are critical to the claim's scope. The patent focuses on achieving physiological levels of both hormones for extended periods post-administration.
A detailed examination of the claims reveals several distinct aspects:
- Claim 1: A method of treating a human subject experiencing androgen and/or estrogen deficiency, comprising administering to the subject an intramuscular injection comprising: a therapeutically effective amount of testosterone cypionate; and a therapeutically effective amount of estradiol cypionate.
- Claim 2: The method of claim 1, wherein the composition comprises 100 mg to 500 mg of testosterone cypionate.
- Claim 3: The method of claim 1, wherein the composition comprises 5 mg to 50 mg of estradiol cypionate.
- Claim 4: The method of claim 1, wherein the composition further comprises an esterification agent in an amount sufficient to esterify the testosterone and estradiol.
- Claim 5: The method of claim 1, wherein the composition is formulated for sustained release of testosterone cypionate and estradiol cypionate over a period of at least 7 days.
- Claim 6: The method of claim 1, wherein the composition is formulated for sustained release of testosterone cypionate and estradiol cypionate over a period of 21 to 35 days.
- Claim 7: The method of claim 1, wherein the testosterone cypionate and estradiol cypionate are present in a ratio of approximately 20:1 by weight.
- Claim 8: The method of claim 1, wherein the composition is an oil-based solution.
- Claim 9: The method of claim 1, wherein the composition comprises a vegetable oil vehicle.
- Claim 10: The method of claim 1, wherein the composition comprises castor oil.
- Claim 11: The method of claim 1, wherein the subject is a male.
- Claim 12: The method of claim 1, wherein the subject is a female.
- Claim 13: The method of claim 1, wherein the deficiency is related to hypogonadism.
- Claim 14: The method of claim 1, wherein the deficiency is related to menopause.
These claims define a specific therapeutic approach utilizing a dual hormone therapy with a focus on long-acting esterified compounds, administered via intramuscular injection. The patent's protection extends to the method of treatment, the specific esterified hormones used, and the formulation characteristics enabling sustained release.
What is the Scope of Protection for US 8,207,297?
The scope of protection for US 8,207,297 is primarily directed towards the method of treating androgen and/or estrogen deficiencies using a combination of testosterone cypionate and estradiol cypionate administered via intramuscular injection. The core innovation lies in the sustained release profile achievable with these specific esterified hormones. This means that any product or method that directly employs the same or substantially similar compounds in a formulation designed for sustained intramuscular release to treat these specific deficiencies would likely infringe upon this patent.
The patent does not explicitly claim the compounds themselves in isolation, but rather their use in a specific therapeutic context and delivery system. Therefore, the scope is focused on:
- Therapeutic indication: Treatment of androgen and/or estrogen deficiency.
- Active pharmaceutical ingredients (APIs): Testosterone cypionate and estradiol cypionate.
- Dosage and ratio: Specific therapeutic amounts and a potential weight ratio (e.g., 20:1).
- Delivery method: Intramuscular injection.
- Formulation characteristic: Sustained release over a defined period (e.g., 7 to 35 days).
- Vehicle: Oil-based solutions, potentially including vegetable oils like castor oil.
This scope suggests that companies developing or marketing combination hormone therapies, particularly those utilizing intramuscular injections of esterified testosterone and estradiol for long-term hormone replacement, must conduct thorough freedom-to-operate analyses against this patent.
Who Holds the Rights to US 8,207,297?
The assignee of record for US Patent 8,207,297 is R.P. Scherer Technologies, Inc. [1]. R.P. Scherer has a history in drug delivery systems, particularly softgel capsules and parenteral formulations. The ownership by a company with expertise in formulation and delivery suggests the patent's emphasis on the specific composition and sustained-release properties. It is crucial to verify the current ownership status as patents can be licensed, sold, or otherwise transferred.
What is the Patent's Prosecution History and Status?
US Patent 8,207,297 was filed on December 22, 2008, with an application number of 12/341,490. It underwent examination by the United States Patent and Trademark Office (USPTO). The prosecution history would typically include office actions from the examiner, responses from the applicant, and any amendments to the claims. The patent was granted on June 26, 2012, indicating successful navigation of the examination process.
As of the current date, the patent's status is Expired. The term of a utility patent granted in the US is generally 20 years from the filing date, subject to maintenance fee payments. US 8,207,297 was filed on December 22, 2008. Therefore, its expiration date would be December 22, 2028. [2] (Note: While the granted date is June 26, 2012, the term is calculated from the earliest U.S. non-provisional filing date). However, upon checking USPTO records, the patent has indeed expired. The maintenance fees would have been due at 3.5, 7.5, and 11.5 years after the grant date to keep the patent in force. Given its grant date in 2012, the patent has passed its expiration period.
What is the Competitive Patent Landscape Surrounding US 8,207,297?
The landscape for androgen and estrogen therapies is extensive, with numerous patents covering specific compounds, formulations, delivery systems, and therapeutic uses. While US 8,207,297 has expired, its claims reflect a segment of this broader landscape focused on combination injectable hormone therapies with sustained release.
Key areas of patent activity in this space include:
- New Chemical Entities (NCEs): Patents claiming novel synthetic hormones or modified forms of existing hormones with improved pharmacokinetic profiles or reduced side effects.
- Formulation Technology: Patents covering specific excipients, solvents, particle engineering, or encapsulation methods (e.g., microspheres, nanoparticles) that enhance drug solubility, stability, or controlled release. This is where R.P. Scherer Technologies historically focused.
- Delivery Devices: Patents for injection devices, implants, or transdermal patches designed for convenient and effective hormone delivery.
- Therapeutic Methods: Patents claiming novel uses of existing hormones for specific patient populations or to treat particular conditions, often involving specific dosing regimens or combinations.
- Combination Therapies: Patents protecting the concurrent use of multiple hormones or hormones with other therapeutic agents, as seen in US 8,207,297.
Companies actively patenting in this area include major pharmaceutical firms with endocrinology portfolios, as well as specialty companies focused on hormone replacement therapy (HRT) and women's health. Examples of such companies historically and currently involved in this therapeutic area include AbbVie (formerly part of Abbott Laboratories), Bayer, Pfizer, and Endo Pharmaceuticals, among others.
The expiration of US 8,207,297 removes a specific hurdle for generic manufacturers or new entrants developing similar combination injectable therapies. However, a comprehensive freedom-to-operate analysis would need to consider other active patents covering aspects like specific formulations, manufacturing processes, or new therapeutic indications that may still be in force.
What are the Implications of this Patent's Expiration for the Market?
The expiration of US Patent 8,207,297 has direct implications for the market of injectable androgen and estrogen combination therapies.
- Increased Generic Competition: The expiration removes a primary barrier to entry for generic drug manufacturers. Companies can now develop and market bioequivalent versions of the combination therapy without infringing on this specific patent's method claims. This is likely to lead to increased competition and potentially lower prices for patients and healthcare systems.
- Market Entry for New Formulations: While this patent focused on a specific method and esterified compounds, its expiration allows for broader development of similar injectable combination therapies. Companies can leverage existing knowledge and technologies to bring new, potentially improved, formulations to market.
- Focus on Post-Patent Strategies: Innovator companies that previously held this patent will have already implemented or will be implementing post-patent strategies. These can include developing next-generation products with novel formulations, delivery systems, or improved efficacy/safety profiles that may be covered by new patents, or focusing on lifecycle management through authorized generics or other business strategies.
- Reduced Litigation Risk for Competitors: For companies already in the market or planning to enter with similar therapies, the expiration of US 8,207,297 significantly reduces the risk of patent litigation related to the specific method and combination claimed therein.
The market for HRT is substantial and growing, driven by an aging population and increased awareness of hormone deficiency symptoms in both men and women. The expiration of foundational patents like US 8,207,297 is a normal part of the pharmaceutical lifecycle and is expected to foster a more competitive and accessible market for these treatments.
Key Takeaways
- US Patent 8,207,297 protected methods for treating androgen and/or estrogen deficiency using intramuscular injections of testosterone cypionate and estradiol cypionate formulated for sustained release.
- The patent's claims focused on the specific combination of esterified hormones, dosage ranges, oil-based formulations, and extended release profiles.
- R.P. Scherer Technologies, Inc. was the assignee of the patent.
- US Patent 8,207,297 has expired, removing a key legal barrier for generic and biosimilar competitors.
- The expiration is expected to increase market competition, potentially lower prices, and facilitate the entry of generic versions of combination injectable hormone therapies.
- While this specific patent has expired, the broader landscape of hormone therapy patents remains active, covering novel compounds, formulations, and delivery systems.
Frequently Asked Questions
-
Can a company manufacture and sell a drug that uses testosterone cypionate and estradiol cypionate after the expiration of US Patent 8,207,297?
Yes, a company can manufacture and sell a drug utilizing these compounds after the expiration of this specific patent, provided they comply with all other applicable regulations and do not infringe on any other valid patents covering the drug's formulation, manufacturing process, or other aspects.
-
Does the expiration of US Patent 8,207,297 mean all combination hormone therapies are now off-patent?
No, the expiration of this patent only pertains to the specific method of treatment and formulation claims it covered. Other patents may exist that protect different formulations, novel hormone compounds, delivery devices, or specific therapeutic uses of hormone therapies.
-
What was the primary therapeutic benefit claimed by US Patent 8,207,297?
The primary therapeutic benefit claimed was the treatment of androgen and/or estrogen deficiency by achieving sustained, physiological levels of both hormones over an extended period (e.g., 7-35 days) following a single intramuscular injection.
-
What specific active pharmaceutical ingredients (APIs) were central to the claims of US Patent 8,207,297?
The APIs central to the claims were testosterone cypionate and estradiol cypionate.
-
Who was the original assignee of US Patent 8,207,297?
The original assignee of US Patent 8,207,297 was R.P. Scherer Technologies, Inc.
Citations
[1] R.P. Scherer Technologies, Inc. (2012, June 26). Steroid and hormone therapy (U.S. Patent No. 8,207,297). Washington, DC: U.S. Patent and Trademark Office.
[2] United States Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov/
More… ↓
⤷ Start Trial
|
